Searching in HEALTH-CANADA · Search everything

Clear filters

10 changes Priority review, last 7 days

Favicon for www.canada.ca

Health Canada Implements ICH Q12 and Q14 Guidance

Health Canada has announced the implementation of International Council for Harmonisation (ICH) Q12 and Q14 guidance. The initial scope focuses on Post Approval Change Management Protocols (PACMPs) for Biologic and Radiopharmaceutical Drugs Directorate products, with further implementation details to follow.

Priority review Notice Pharmaceuticals
Favicon for www.canada.ca

ICH Consultations on Patient Preference, Extractables, and Adaptive Trials

Health Canada announced three International Council for Harmonisation (ICH) draft guidelines are open for public consultation. The consultations cover patient preference studies, extractables and leachables, and adaptive clinical trials, with comment deadlines ranging from November 2025 to April 2026.

Priority review Consultation Pharmaceuticals
Favicon for www.canada.ca

Health Canada Implements ICH Pharmaceutical Guidelines

Health Canada is implementing new International Council for Harmonisation (ICH) guidelines for pharmaceuticals, including M13A and Q12/Q14. These implemented ICH guidelines will take precedence over existing Health Canada guidance documents where discrepancies exist, potentially leading to amendments or withdrawals of current guidance.

Priority review Guidance Pharmaceuticals
Favicon for www.canada.ca

Health Canada Proposes Reliance on Foreign Drug Authority Decisions

Health Canada is proposing a new Ministerial Reliance Order (MRO) that would allow the Minister to examine new drug submissions by relying on decisions from foreign regulatory authorities. This initiative is part of a broader Red Tape Review aimed at facilitating earlier drug availability in Canada while maintaining safety and quality standards. A 70-day consultation period is currently underway.

Priority review Consultation Healthcare
Favicon for recalls-rappels.canada.ca

Ford Truck Recall - Backup Alarm May Not Sound

Transport Canada has issued a recall (2026096) for certain Ford trucks where a loose electrical connector may prevent the backup alarm from sounding. This poses a safety risk to road users. Ford will notify owners to have the connector replaced at a dealership.

Priority review Notice Transportation
Favicon for recalls-rappels.canada.ca

Transport Canada Recall: Ford SUV Infotainment System Overheating

Transport Canada has issued a recall for certain Ford SUVs due to an overheating infotainment system that may affect the rearview camera display. Ford will notify owners to update the vehicle's software to address the safety risk.

Priority review Notice Transportation
Favicon for recalls-rappels.canada.ca

Transport Canada Recall: Ford SUV Seats

Transport Canada has issued a recall for certain Ford SUVs due to a potential issue with the driver's seat that could cause a loss of control. Ford will notify owners and provide a software update to correct the defect.

Priority review Notice Transportation
Favicon for www.canada.ca

Health Canada Health Product Safety Recap

Health Canada has issued its February 2026 Health Product InfoWatch, detailing recalls for Teva Octreotide due to GMP deficiencies and unauthorized health products. It also announces a consultation on controlling zuranolone under the Controlled Drugs and Substances Act.

Priority review Notice Pharmaceuticals
Favicon for www.canada.ca

Health Canada Health Product InfoWatch - February 2026

Health Canada's February 2026 Health Product InfoWatch includes a monthly recap of safety information, including a recall of Teva Octreotide and advisories on unauthorized products. It also announces a consultation on controlling zuranolone and new market authorizations with conditions.

Priority review Notice Pharmaceuticals
Favicon for recalls-rappels.canada.ca

Chikungunya Vaccine IXCHIQ: Risks for Frail Seniors 65+

Health Canada has issued updated safety information regarding the chikungunya vaccine IXCHIQ. Medically frail individuals aged 65 and older may be at increased risk of serious adverse reactions. Healthcare professionals are advised to carefully assess risks and benefits for this demographic.

Priority review Notice Public Health

Get alerts for ""

We'll email you when new changes match this search.

Free. Unsubscribe anytime.